Replimune Group (NASDAQ:REPL) Stock Price Up 10.9% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s share price rose 10.9% during mid-day trading on Friday . The company traded as high as $8.14 and last traded at $8.02. Approximately 279,967 shares traded hands during trading, a decline of 67% from the average daily volume of 835,814 shares. The stock had previously closed at $7.23.

Wall Street Analysts Forecast Growth

REPL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright increased their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Up 8.6%

The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $604.57 million, a P/E ratio of -2.56 and a beta of 0.68. The firm has a 50-day moving average price of $8.95 and a two-hundred day moving average price of $11.32.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Exome Asset Management LLC raised its stake in shares of Replimune Group by 438.6% in the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock valued at $2,875,000 after purchasing an additional 240,108 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Replimune Group in the first quarter valued at $343,000. Parkman Healthcare Partners LLC raised its stake in shares of Replimune Group by 9.3% in the first quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock valued at $9,266,000 after purchasing an additional 80,640 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.